SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug Bean who wrote (721)4/4/1998 8:35:00 PM
From: tommysdad  Read Replies (1) of 1837
 
AHP has launched a fairly major ad campaign promoting Premarin aimed squarely at Evista, a nonsteroidal selective estrogen receptor modulator from Lilly. The ads I have seen mention all the areas in a women's body that respond well to estrogen -- the implication being Evista won't have those same beneficial effects. What the ads don't show is the reported increased uterine cancer risk -- which is the whole idea behind Lilly's Evista.

BTW, don't jump on increased uterine cancer risk due to Premarin as a potential advantage of DRMD's product. There is no reason to expect Cenestin to be any better than Premarin (after all, DRMD originally went after equivalency). I assume most MD's will prescribe a progestin along with Cenestin to address this issue.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News